Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).
J. Bernhard(International Breast Cancer Study Group), Thomas Ruhstaller(University Hospital Bonn), Fabio Puglisi(University of Udine), Meredith M. Regan(Dana-Farber Cancer Institute), Lorenzo Pavesi(University of Trento), Vani Parmar(Homi Bhabha National Institute), Prudence A. Francis(Peter MacCallum Cancer Centre), Barbara Walley, Richard D. Gelber(Harvard University), Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Marco Colleoni(European Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), Simon Spazzapan(Centro di Riferimento Oncologico), Olivia Pagani(Swiss Group For Clinical Cancer Research), Alan S. Coates(International Breast Cancer Study Group), Weixiu Luo(Dana-Farber Cancer Institute), Graziella Pinotti(Medica (Italy)), Karin Ribi, Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 14
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k